IntelGenx Corp. Forms Strategic Agreement with Azur Pharma to Develop Prenatal Vitamin Supplements Addressing a U.S. Market of $250 million

January 07, 2008

Saint Laurent, Quebec, January 7, 2008 - IntelGenx Corp. (OTCBB:IGXT) ("IntelGenx" or the "Company") has formed a strategic agreement with Azur Pharma to develop and commercialize prenatal vitamin supplements using IntelGenx’s proprietary oral delivery technology.

Horst G. Zerbe, President and CEO of IntelGenx, said, “This agreement marks an important milestone for IntelGenx, as it represents the commercialization of the first product using our drug delivery technologies.”

Under the strategic agreement, the companies expect to launch two products in the first half of 2008.  IntelGenx will complete the development of the products, using its patented proprietary delivery technologies, and will be entitled to royalties on Azur’s net U.S. revenues from the products.  Azur will be responsible for commercialization and marketing activities in the U.S.

A leading global services and publishing company estimates the U.S. market size for prenatal vitamins at $250 million annually.  IntelGenx management anticipates rapid penetration of the market, achieving significant sales over the first five years of commercialization.

Dr. Zerbe stated, “We are indeed pleased to partner with Azur Pharma, which is noted for its strong U.S. national sales infrastructure and its wide-ranging portfolio of products addressing women’s health.  Our innovative oral, immediate-release and controlled-release delivery technologies add important new options to their portfolio.”

About Intelgenx Corp.
IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films.  The company’s research and development pipeline includes products for the treatment of osteoarthritis, pain management, hypertension, and smoking cessation. More information is available about the company at and at

About Azur International II Ltd., Inc.

Azur Pharma is a privately held pharmaceutical company dedicated to enhancing patients’ lives by developing and marketing pharmaceutical products in specialist therapeutic areas. Azur Pharma’s strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development and approved pharmaceutical products. (For more information, please visit



IntelGenx Corp.
Dr. Horst G. Zerbe, President and CEO
T: 514-331-7440 (ext. 201)
F: 514-331-0436

Investor Relations:
Consulting for Strategic Growth 1
Stanley Wunderlich, CEO
(212) 337-8089 (FAX)
Media Relations:
Consulting for Strategic Growth 1
Daniel Stepanek
(212) 896-1202
(212) 337-8089 (FAX)